

APOA5 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP7412a**Specification**

APOA5 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q6Q788](#)**APOA5 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 116519**Other Names**

Apolipoprotein A-V, Apo-AV, ApoA-V, Apolipoprotein A5, Regeneration-associated protein 3, APOA5, RAP3

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7412a](/products/AP7412a) was selected from the N-term region of human APOA5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APOA5 Antibody (N-term) Blocking Peptide - Protein Information**Name** APOA5**Synonyms** RAP3**Function**

Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin (PubMed:<http://www.uniprot.org/citations/17326667>).

Cellular Location

Secreted. Early endosome. Late endosome. Golgi apparatus, trans-Golgi network. Note=In the presence of SORL1, internalized to early endosomes, sorted in a retrograde fashion to late endosomes, from which a portion is sent to lysosomes and degradation, another portion is sorted to the trans-Golgi network

Tissue Location

Liver and plasma.

APOA5 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

APOA5 Antibody (N-term) Blocking Peptide - Images**APOA5 Antibody (N-term) Blocking Peptide - Background**

APOA5 is an apolipoprotein and an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury.

APOA5 Antibody (N-term) Blocking Peptide - References

Dorfmeister,B., (er) Arterioscler. Thromb. Vasc. Biol. (2008) In press PUBMED 18635818Wang,J., (er) Hum. Mol. Genet. (2008) In pressHubacek,J.A., Clin. Chem. Lab. Med. 46 (6), 773-777 (2008)